[A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].
Cefmetazole has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic. However, cefmetazole is not an antibiotic to be administered primarily as a preventive. It should be used mainly in treating other agents resistant Gram-negative bacilli infections. In doing so, cefmetazole will become highly useful. 2. The safe dose of cefmetazole (CMZ) to the mother in the perinatal period is 1 approximately equal to 2 g/day. The administration of 4 g/day in a severe case is not contraindicated. 2. The fetus showed no signs of distress or side effects from cefmetazole (CMZ) crossing the mother's placental barrier. The transition of cefmetazole (CMZ) into the mother's milk is insignificant quantitatively but remains unknown qualitatively.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000633:toxicity*; D001424:Bacterial Infections / Q000517:prevention & control; D015311:Cefmetazole; D002511:Cephalosporins / Q000633:toxicity*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011263:Pregnancy Trimester, Third
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D015311:Cefmetazole